☆ 4.5 Article

Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors

EUROPEAN UROLOGY FOCUS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Urology & Nephrology

Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials

Alessandro Rizzo et al.

Summary: This study conducted a meta-analysis to explore the predictive value of immune checkpoint inhibitors (ICI) plus tyrosine kinase inhibitors (TKI) in the treatment of metastatic renal cell carcinoma (mRCC) patients. The results showed that the combination therapy had significant survival benefits in different clinicopathological subgroups.

EUROPEAN UROLOGY FOCUS (2022)

添加到收藏夹

Review Health Care Sciences & Services

Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis

Matteo Santoni et al.

Summary: Results of the need for treatment (NNT) and the need for harm (NNH) analyses reveal the varying efficacy and safety profiles of different combination therapies in metastatic renal cell carcinoma (mRCC), providing valuable insights for clinical trials interpretation.

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2022)

添加到收藏夹

Article Medicine, General & Internal

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

Matteo Santoni et al.

Summary: This study retrospectively analyzed advanced RCC patients receiving cabozantinib treatment, showing that a BMI >= 25 is associated with longer survival. BMI could serve as a significant predictor for prognosis in advanced RCC patients.

DIAGNOSTICS (2021)

添加到收藏夹

Letter Urology & Nephrology

Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy

Matteo Santoni et al.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert Motzer et al.

Summary: The study demonstrated that the combination of lenvatinib with pembrolizumab led to significantly longer progression-free survival and overall survival than sunitinib, while the combination of lenvatinib with everolimus showed longer progression-free survival but not overall survival compared to sunitinib. Adverse events were more frequent in patients receiving lenvatinib-based treatments.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Oncology

Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review

Alessandro Rizzo et al.

Summary: Recent years have shown a growing focus on quality of life (QoL) in medical oncology clinical trials and the statistical measurement of this element of cancer treatment. However, the inclusion of QoL results in clinical trials is still lacking, highlighting the urgent need for implementation in this area.

FUTURE ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news

Francisco Zambrana et al.

Summary: The use of immune-checkpoint inhibitors in mRCC has led to better survival outcomes and higher rates of complete responses, but also presents challenges in defining durable responses, optimal treatment duration, and the value of complete responses. Questions remain regarding whether complete responses can be considered as a cure and if immunotherapy discontinuation should be considered after achieving a complete response.

CANCER TREATMENT REVIEWS (2021)

添加到收藏夹

Article Oncology

Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials

Francesco Massari et al.

Summary: This study conducted a meta-analysis on the latest clinical trial data of immune-based combinations in mRCC, demonstrating the significant advantages of immune-based combinations in reducing the risk of death and extending PFS, as well as improving CR rate and ORR.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States

Matteo Santoni et al.

Summary: The incidence of renal-cell carcinoma (RCC) is increasing, and an artificial neural network was implemented to predict new cases in the population based on demographic and health data. Preventing hypertension was found to have the greatest impact on reducing RCC incidence, highlighting the importance of studying risk factors for accurate prevention efforts.

CLINICAL GENITOURINARY CANCER (2021)

添加到收藏夹

Article Oncology

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

Matteo Santoni et al.

CANCERS (2020)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Brian I. Rini et al.

LANCET (2019)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Urology & Nephrology

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer

Francesco Soria et al.

WORLD JOURNAL OF UROLOGY (2018)

添加到收藏夹

Review Oncology

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

Michael M. Boyiadzis et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Padmanee Sharma et al.

CELL (2017)

添加到收藏夹

Article Oncology

RECIST 1.1-Update and clarification: From the RECIST committee

Lawrence H. Schwartz et al.

EUROPEAN JOURNAL OF CANCER (2016)

添加到收藏夹

Article Urology & Nephrology

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours

Holger Moch et al.

EUROPEAN UROLOGY (2016)

添加到收藏夹

Article Oncology

Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma

Daniele Santini et al.

ONCOTARGET (2016)

添加到收藏夹

Article Urology & Nephrology

Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma

Matteo Santoni et al.

JOURNAL OF UROLOGY (2015)

添加到收藏夹

Review Oncology

Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside

Matteo Santoni et al.

CANCER AND METASTASIS REVIEWS (2014)

添加到收藏夹

Review Oncology

Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials

Roberto Iacovelli et al.

CANCER TREATMENT REVIEWS (2014)

添加到收藏夹

Article Oncology

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

D. Y. Heng et al.

ANNALS OF ONCOLOGY (2012)

添加到收藏夹

Review Oncology

Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science

Camillo Porta et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2012)

添加到收藏夹

Article Medicine, General & Internal

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Marco Gerlinger et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Review Oncology

Renal cell carcinoma

Jorge A. Garcia et al.

CURRENT OPINION IN ONCOLOGY (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.